Indication | Compounds | Marine organism source | Mechanism of action | Current status | References |
---|---|---|---|---|---|
Anticancer | Aplidine (Aplidin®) (dehydrodidemnin B) | Aplidium, Candida albicans Mediterranean tunicate | Antiproliferative action. Acts by blocking the cell cycle arrest and inducing apoptosis | Multiple myeloma (Phase III of clinical trials) T-cell lymphoma (Phase II of clinical trials) | |
Plinabulin | Synthetic analog of a natural product isolated from a marine fungus (Aspergillus spp.) | Inhibition of tubulin polymerization Non-small cell lung cancer (Phase III of clinical trials) | Non-small cell lung cancer (Phase III of clinical trials) | [13] | |
Salinosporamide A (NPI-0052/Marizomib) | Marine Actinobacteria Salinispora tropica | Proteasome inhibitor | Multiple myeloma (Phase I of clinical trials) | ||
Dolstatin 10 | Sea hare Dolabella auricularia, a cyanobacterial origin | Inhibition of the tubulin polymerization and GTP hydrolysis | Phase I and II but it failed in phase II, however, Dolstatins are in phase III trials | ||
Dolstatin 15 | Sea hare Dolabella auricularia | Antimitotic and capable of disrupting tubulin polymerization | Phase II clinical trials | ||
Coibamide A | Leptolyngbya cyanobacterium | Induce apoptosis | Under preclinical investigation | ||
Alzheimer’s disease | Bryostatin 1, | Ectoprocta species‑Bugula Neritina | Potent modulator of protein kinase C | Phase II of clinical trials | [45] |
DMXB-A | Synthetic analog of the toxic alkaloid produced by nemertines worm species, such as Paranemertes peregrine and Amphiporus lactifloreu | Acts by improving cognition and sensory deficit | Phase I and II of clinical trials completed | ||
Analgesics | Tetrodotoxin | Isolated from fish, algae, and bacteria | Blocks voltage‑dependent sodium channels | Phase II and III of clinical trials for neuropathic pain in cancer patients and peripheral neuralgia in cancer patients, respectively | [45] |
Antibacterial | Anthracimycin | Marine Actinobacteria | Activity against Bacillus anthracis and MRSA. MoA unclear | Preliminary stages of drug development | [45] |